MDAIW Overview

Funding Announcement: Spectral AI, Inc. has priced a $7.6 million offering to support the growth and development of its DeepView® System, which focuses on medical diagnostics in wound care.

Share Issuance Details: The offering includes the issuance of 4,000,000 shares of common stock at $1.90 per share, along with corresponding warrants for future exercise.

Company Commitment: Chairman J. Michael DiMaio expressed confidence in securing institutional funding, emphasizing the company's commitment to advancing the DeepView System and supporting its BARDA Project BioShield contract.

About DeepView System: The DeepView System aims to provide clinicians with immediate assessments of burn wounds' healing potential, improving patient outcomes and reducing healthcare costs through algorithm-driven insights.

Recognition of Spectral AI: Spectral AI, Inc. has been named to TIME's World's Top HealthTech Companies 2025 list, highlighting its innovative contributions to medical diagnostics in wound care.

DeepView Technology: The company's DeepView System aims to revolutionize wound management by providing predictive assessments of burn wounds, enhancing treatment decisions and potentially improving patient outcomes while reducing healthcare costs.

Spectral AI's Role at EBA Conference: Spectral AI showcased its advancements in burn care at the European Burns Association conference in Berlin, featuring multiple presentations on its DeepView technology, which enhances burn wound assessment through artificial intelligence and multispectral imaging.

Impact of DeepView Technology: The DeepView System aims to provide clinicians with objective assessments of burn wounds' healing potential, potentially improving patient outcomes and reducing healthcare costs, as highlighted by various studies presented at the conference.

FDA Submission: Spectral AI has submitted a De Novo 510k marketing clearance application to the FDA for its DeepView® System, an AI-driven device designed to predict burn healing potential in clinical settings, marking a significant milestone for the company.

Technology Overview: The DeepView System utilizes multi-spectral imaging and AI algorithms to provide non-invasive assessments of burn wounds, enabling clinicians to make informed treatment decisions quickly, potentially improving patient outcomes and reducing healthcare costs.

Leadership Announcement: Stanley Micek has been appointed as the Chief Operating Officer of Spectral AI, Inc., after serving as Interim COO since May 2024, reflecting his strong leadership and operational insight in advancing the company's medical diagnostics initiatives.

Company Focus: Spectral AI is dedicated to revolutionizing wound care through its DeepView® System, which aims to provide clinicians with immediate assessments of burn wounds' healing potential, ultimately improving patient outcomes and reducing healthcare costs.

DeepView System's Clinical Success: Spectral AI's DeepView System, which utilizes multi-spectral imaging and AI algorithms for assessing burn healing potential, achieved a 95.3% accuracy in a clinical study published in the journal Burns, highlighting its effectiveness over traditional methods.

Impact on Burn Care: The technology is poised to revolutionize burn management by providing clinicians with data-driven insights for better decision-making regarding treatment, ultimately improving patient outcomes and reducing healthcare costs.